Amgen, MD Anderson Launch Two Cancer Collaborations

Amgen and The University of Texas MD Anderson Cancer Center said they have launched two collaborations of undisclosed value that are intended to speed up development of the biotech giant’s early-stage oncology therapies.The therapies—which are either nearing or just beginning clinical development—have been generated by Amgen's bispecific T-cell engager (BiTE ® ), chimeric antigen receptor (CAR) T-cell, and small-molecule programs. The collaborations will combine candidates